Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > As always, nothing going on
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Post by zwerp2000on Dec 13, 2021 11:05am
178 Views
Post# 34224965

As always, nothing going on

As always, nothing going onJD continues to suggest, as he's been doing for over 10 years, that he has connected the dots and that investors are not smart enough to see what is going on

Chiasi deal was signed over 1 1/2 years ago and not one update

Nothing on Prothena in years

Stock near a 52 wk low

No volume

No new partnerships

After 10+ years, no drugs in the clinic. It's amazing how many of you longs still don't find it strange there are no drugs in the clinic despite the company telling you for years it was going to happen soon

Go back and listen to the last annual shareholders meeting given by your wonderful CEO and see how much she said came to fruition. I am sure she will say the same things again, kicking the timelines back as usual. When will you hold her feet to the fire?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities